Enrolled Copy H.B. 175

1	OPIOID AB	USE PREVENTION AN	ID TREATMENT	
2		AMENDMENTS		
3	2017 GENERAL SESSION			
4	STATE OF UTAH			
5	Chief Sponsor: Steve Eliason			
6	Se	enate Sponsor: Brian E. Sl	hiozawa	
7	Cosponsors:	Craig Hall	Michael E. Noel	
8	Rebecca Chavez-Houck	Sandra Hollins		
9	Brad M. Daw	Michael S. Kennedy		
10				
11	LONG TITLE			
12	General Description:			
13	This bill requires controlled substance prescribers to receive training in a nationally			
14	recognized opioid abuse screening method and requires reimbursement for the			
15	screening services.			
16	Highlighted Provisions:			
17	This bill:			
18	 requires controlled su 	ubstance prescribers to receive	training in a nationally	
19	recognized opioid abuse screening method;			
20	 permits controlled su 	bstance prescribers to fulfill co	ontinuing education requirements	
21	through training in the screening	g method;		
22	 permits controlled su 	bstance prescribers who receive	ve a DATA 2000 waiver to use	
23	the waiver to fulfill certain conti	the waiver to fulfill certain continuing education requirements;		
24	 requires Medicaid re 	imbursement to health care pro	oviders for screening services;	
25	• requires the Public E	mployees' Benefit and Insuran	ce Program to reimburse health	
26	care providers for screening serv	vices; and		
27	makes technical char	iges.		
28	Money Appropriated in this B	ill:		

29	None		
30	Other Special Clauses:		
31	None		
32	Utah Code Sections Affected:		
33	AMENDS:		
34	58-37-6.5, as repealed and reenacted by Laws of Utah 2013, Chapter 450		
35	ENACTS:		
36	26-18-21 , Utah Code Annotated 1953		
37	49-20-414 , Utah Code Annotated 1953		
38			
39	Be it enacted by the Legislature of the state of Utah:		
40	Section 1. Section 26-18-21 is enacted to read:		
41	26-18-21. Screening, Brief Intervention, and Referral to Treatment Medicaid		
42	reimbursement.		
43	(1) As used in this section:		
44	(a) "Controlled substance prescriber" means a controlled substance prescriber, as that		
45	term is defined in Section 58-37-6.5, who:		
46	(i) has a record of having completed SBIRT training, in accordance with Subsection		
47	58-37-6.5(2), before providing the SBIRT services; and		
48	(ii) is a Medicaid enrolled health care provider.		
49	(b) "SBIRT" means the same as that term is defined in Section 58-37-6.5.		
50	(2) The department shall reimburse a controlled substance prescriber who provides		
51	SBIRT services to a Medicaid enrollee who is 13 years of age or older for the SBIRT services.		
52	Section 2. Section 49-20-414 is enacted to read:		
53	49-20-414. Screening, Brief Intervention, and Referral to Treatment program		
54	reimbursement.		
55	(1) As used in this section:		
56	(a) "Controlled substance prescriber" means a controlled substance prescriber, as that		

H.B. 175

Enrolled Copy

Enrolled Copy H.B. 175

7	term is defined in Section 58-37-6.5, who:
8	(i) has a record of having completed SBIRT training, in accordance with Subsection
9	58-37-6.5(2), before providing the SBIRT services; and
0	(ii) is a program enrolled controlled substance prescriber.
1	(b) "SBIRT" means the same as that term is defined in Section 58-37-6.5.
2	(2) The health program offered to the state employee risk pool under Section
3	49-20-202 shall reimburse a controlled substance prescriber who provides SBIRT services to a
4	covered individual who is 13 years of age or older for the SBIRT services.
5	Section 3. Section 58-37-6.5 is amended to read:
6	58-37-6.5. Continuing education for controlled substance prescribers.
7	(1) For the purposes of this section:
8	(a) "Controlled substance prescriber" means an individual, other than a veterinarian,
9	who:
0	(i) is licensed to prescribe a controlled substance under Title 58, Chapter 37, Utah
1	Controlled Substances Act; and
2	(ii) possesses the authority, in accordance with the individual's scope of practice, to
3	prescribe schedule II controlled substances and schedule III controlled substances that are
4	applicable to opioid narcotics, hypnotic depressants, or psychostimulants.
5	(b) "D.O." means an osteopathic physician and surgeon licensed under Title 58,
6	Chapter 68, Utah Osteopathic Medical Practice Act.
7	[(b)] (c) "FDA" means the United States Food and Drug Administration.
8	[(c)] (d) "M.D." means a physician and surgeon licensed under Title 58, Chapter 67,
9	Utah Medical Practice Act.
0	[(d) "D.O." means an osteopathic physician and surgeon licensed under Title 58,
1	Chapter 68, Utah Osteopathic Medical Practice Act.]
2	(e) "SBIRT" means the Screening, Brief Intervention, and Referral to Treatment
3	approach used by the federal Substance Abuse and Mental Health Services Administration or
4	defined by the division, in consultation with the Division of Substance Abuse and Mental

H.B. 175 Enrolled Copy

85	Health, by administrative rule, in accordance with Title 63G, Chapter 3, Utah Administrative	
86	Rulemaking Act.	
87	(2) (a) Beginning with the licensing period that begins after January 1, 2014, as a	
88	condition precedent for license renewal, each controlled substance prescriber shall complete at	
89	least four continuing education hours per licensing period that satisfy the requirements of	
90	Subsections (3) and (4).	
91	(b) (i) Beginning with the licensing period that begins after January 1, 2024, as a	
92	condition precedent for license renewal, each controlled substance prescriber shall complete at	
93	<u>least 3.5 continuing education hours in an SBIRT-training class that satisfies the requirements</u>	
94	of Subsection (5).	
95	(ii) Completion of the SBIRT-training class, in compliance with Subsection (2)(b)(i),	
96	fulfills the continuing education hours requirement in Subsection (4) for the licensing period in	
97	which the class was completed.	
98	(iii) A controlled substance prescriber:	
99	(A) need only take the SBIRT-training class once during the controlled substance	
100	prescriber's licensure in the state; and	
101	(B) shall provide a completion record of the SBIRT-training class in order to be	
102	reimbursed for SBIRT services to patients, in accordance with Section 26-18-21 and Section	
103	<u>49-20-414.</u>	
104	(3) As provided in Subsection 58-37f-402(8), the online tutorial and passing the online	
105	test described in Section 58-37f-402 shall count as 1/2 hour of continuing professional	
106	education under Subsection (2) per licensing period.	
107	(4) A controlled substance prescriber shall complete at least 3.5 hours of continuing	
108	education [hours] in one or more controlled substance prescribing classes, except dentists who	
109	shall complete at least $[\frac{2 \text{ such}}{2 \text{ such}}]$ $\underline{\text{two}}$ hours, that satisfy the requirements of Subsections (5) and	
110	(7).	
111	(5) A controlled substance prescribing class shall:	
112	(a) satisfy the division's requirements for the continuing education required for the	

Enrolled Copy H.B. 175

113 renewal of the controlled substance prescriber's respective license type; 114 (b) be delivered by an accredited or approved continuing education provider recognized by the division as offering continuing education appropriate for the controlled 115 116 substance prescriber's respective license type; and 117 (c) include a postcourse knowledge assessment. 118 (6) An M.D. or D.O. completing continuing professional education hours under 119 Subsection (4) shall complete those hours in classes that qualify for the American Medical 120 Association Physician's Recognition Award Category 1 Credit. 121 (7) The 3.5 hours of the controlled substance prescribing classes under Subsection (4) 122 shall include educational content covering the following: (a) the scope of the controlled substance abuse problem in Utah and the nation; 123 124 (b) all elements of the FDA Blueprint for Prescriber Education under the FDA's 125 Extended-Release and Long-Acting Opioid Analgesics Risk Evaluation and Mitigation Strategy, as published July 9, 2012, or as it may be subsequently revised: 126 (c) the national and Utah-specific resources available to prescribers to assist in 127 128 appropriate controlled substance and opioid prescribing; 129 (d) patient record documentation for controlled substance and opioid prescribing; and (e) office policies, procedures, and implementation. 130 131 (8) (a) The division, in consultation with the Utah Medical Association Foundation, 132 shall determine whether a particular controlled substance prescribing class satisfies the educational content requirements of Subsections (5) and (7) for an M.D. or D.O. 133 (b) The division, in consultation with the applicable professional licensing boards. 134 135 shall determine whether a particular controlled substance prescribing class satisfies the 136 educational content requirements of Subsections (5) and (7) for a controlled substance 137 prescriber other than an M.D. or D.O.

(c) The division may by rule establish a committee that may audit compliance with the

Utah Risk Evaluation and Mitigation Strategy (REMS) Educational Programming Project

grant, that satisfies the educational content requirements of Subsections (5) and (7) for a

138

139

140

H.B. 175 Enrolled Copy

141	controlled substance prescriber.
142	(9) A controlled substance prescribing class required under this section:
143	(a) may be held:
144	(i) in conjunction with other continuing professional education programs; and
145	(ii) online; and
146	(b) does not increase the total number of state-required continuing professional
147	education hours required for prescriber licensing.
148	(10) The division may establish rules, in accordance with Title 63G, Chapter 3, Utah
149	Administrative Rulemaking Act, to implement this section.
150	(11) A controlled substance prescriber who, on or after July 1, 2017, obtains a waiver
151	to treat opioid dependency with narcotic medications, in accordance with the Drug Addiction
152	Treatment Act of 2000, 21 U.S.C. Sec. 823 et seq., may use the waiver to satisfy the 3.5 hours
153	of the continuing education requirement under Subsection (4) for two consecutive licensing
154	periods